<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>49(1-2)</volume><submitter>Bhat V</submitter><pubmed_abstract>The current strategy for treating the Covid-19 coronavirus disease involves the repurposing of existing drugs or the use of convalescent plasma therapy, as no specific therapeutic intervention has yet received regulatory approval. However, severe adverse effects have been reported for some of these repurposed drugs. Recently, several &lt;i>in silico&lt;/i> studies have identified compounds that are potential inhibitors of the main protease (3-chymotrypsin-like cysteine protease) and the nucleocapsid protein of SARS-CoV-2. An essential step of drug development is the careful evaluation of toxicity, which has a range of associated financial, temporal and ethical limitations. In this study, a number of &lt;i>in silico&lt;/i> tools were used to predict the toxicity of 19 experimental compounds. A range of</pubmed_abstract><journal>Alternatives to laboratory animals : ATLA</journal><pagination>22-32</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8047515</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The Use of &lt;i>In Silico&lt;/i> Tools for the Toxicity Prediction of Potential Inhibitors of SARS-CoV-2.</pubmed_title><pmcid>PMC8047515</pmcid><pubmed_authors>Chatterjee J</pubmed_authors><pubmed_authors>Bhat V</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Use of &lt;i>In Silico&lt;/i> Tools for the Toxicity Prediction of Potential Inhibitors of SARS-CoV-2.</name><description>The current strategy for treating the Covid-19 coronavirus disease involves the repurposing of existing drugs or the use of convalescent plasma therapy, as no specific therapeutic intervention has yet received regulatory approval. However, severe adverse effects have been reported for some of these repurposed drugs. Recently, several &lt;i>in silico&lt;/i> studies have identified compounds that are potential inhibitors of the main protease (3-chymotrypsin-like cysteine protease) and the nucleocapsid protein of SARS-CoV-2. An essential step of drug development is the careful evaluation of toxicity, which has a range of associated financial, temporal and ethical limitations. In this study, a number of &lt;i>in silico&lt;/i> tools were used to predict the toxicity of 19 experimental compounds. A range of</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jan-Mar</publication><modification>2025-04-05T16:18:17.241Z</modification><creation>2022-02-09T15:46:56.281Z</creation></dates><accession>S-EPMC8047515</accession><cross_references><pubmed>33845649</pubmed><doi>10.1177/02611929211008196</doi></cross_references></HashMap>